Literature DB >> 10203203

The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test.

P Hobson1, J Meara.   

Abstract

AIM: To assess cognitive function in elderly subjects with clinically probable Parkinson's disease (PD).
METHODS: A community sample of 126 patients with probable PD completed the CAMCOG, which is the cognitive section of the Cambridge Examination for Mental Disorders, and the Mini-Mental State Examination (MMSE). The performance of the CAMCOG and the MMSE in detecting dementia in this subject group was compared with the results of applying the DSM-IV criteria for dementia to this population.
RESULTS: A total of 44% of the group met DSM-IV criteria for dementia, which is higher than most previous prevalence figures for dementia in PD. The CAMCOG was more sensitive than the MMSE in detecting cognitive impairment and more specific than the MMSE in detecting dementia as defined by DSM-IV criteria. Poorer performance on the CAMCOG was related to gender, social class and age (P<0.05). Among subjects with PD, those with dementia, as defined by DSM-IV criteria, were significantly older, had greater depressive symptomatology and had greater motor deficits. A greater proportion of the group with dementia were living in residential care (P<0.05).
CONCLUSION: The CAMCOG appears to be a useful screening instrument for dementia and cognitive impairment in PD. Furthermore, it may prove helpful in detecting those with PD who may be at risk of developing dementia and in longitudinal studies of cognitive function in PD.

Entities:  

Mesh:

Year:  1999        PMID: 10203203     DOI: 10.1093/ageing/28.1.39

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  22 in total

1.  Apathy in Parkinson's disease.

Authors:  G C Pluck; R G Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?

Authors:  Francesca Di Biasio; Nicola Vanacore; Alfonso Fasano; Nicola Modugno; Barbara Gandolfi; Francesco Lena; Giovanni Grillea; Sara Pietracupa; Giovanni Caranci; Stefano Ruggieri
Journal:  J Neural Transm (Vienna)       Date:  2011-12-13       Impact factor: 3.575

Review 3.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

4.  Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA.

Authors:  B Hanna-Pladdy; A Enslein; M Fray; B J Gajewski; R Pahwa; K E Lyons
Journal:  Int J Neurosci       Date:  2010-08       Impact factor: 2.292

5.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 6.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

Review 7.  Prion-like mechanisms in neurodegenerative diseases.

Authors:  Bess Frost; Marc I Diamond
Journal:  Nat Rev Neurosci       Date:  2009-12-23       Impact factor: 34.870

8.  Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  J Am Geriatr Soc       Date:  2008-12-10       Impact factor: 5.562

Review 9.  Applications of technology in neuropsychological assessment.

Authors:  Carolyn M Parsey; Maureen Schmitter-Edgecombe
Journal:  Clin Neuropsychol       Date:  2013-09-16       Impact factor: 3.535

10.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.